801 related articles for article (PubMed ID: 19448055)
1. Predicting and preventing the future: actively managing multiple sclerosis.
Hutchinson M
Pract Neurol; 2009 Jun; 9(3):133-43, discussion 144. PubMed ID: 19448055
[TBL] [Abstract][Full Text] [Related]
2. Natural history of multiple sclerosis: a unifying concept.
Confavreux C; Vukusic S
Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
[TBL] [Abstract][Full Text] [Related]
3. [Immunomodulatory therapy in multiple sclerosis].
Csépány T; Bereczki D
Ideggyogy Sz; 2004 Nov; 57(11-12):401-16. PubMed ID: 15662768
[TBL] [Abstract][Full Text] [Related]
4. Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials.
Bates D
Neurology; 2011 Jan; 76(1 Suppl 1):S14-25. PubMed ID: 21205678
[TBL] [Abstract][Full Text] [Related]
5. Clinically isolated syndromes: predicting and delaying multiple sclerosis.
Thrower BW
Neurology; 2007 Jun; 68(24 Suppl 4):S12-5. PubMed ID: 17562845
[TBL] [Abstract][Full Text] [Related]
6. A practical approach to immunomodulatory therapy for multiple sclerosis.
Burks JS
Phys Med Rehabil Clin N Am; 2005 May; 16(2):449-66, ix. PubMed ID: 15893681
[TBL] [Abstract][Full Text] [Related]
7. Switching to second-line therapies in interferon-beta-treated relapsing-remitting multiple sclerosis patients.
Portaccio E; Zipoli V; Siracusa G; Sorbi S; Amato MP
Eur Neurol; 2009; 61(3):177-82. PubMed ID: 19129705
[TBL] [Abstract][Full Text] [Related]
8. MRI as an outcome in multiple sclerosis clinical trials.
Daumer M; Neuhaus A; Morrissey S; Hintzen R; Ebers GC
Neurology; 2009 Feb; 72(8):705-11. PubMed ID: 19073945
[TBL] [Abstract][Full Text] [Related]
9. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Goretti B; Caniatti L; Di Monte E; Ferrazza P; Brescia Morra V; Lo Fermo S; Picconi O; Luccichenti G;
Mult Scler; 2009 Jul; 15(7):779-88. PubMed ID: 19542262
[TBL] [Abstract][Full Text] [Related]
10. Predicting beta-interferon failure in relapsing-remitting multiple sclerosis.
O'Rourke K; Walsh C; Antonelli G; Hutchinson M
Mult Scler; 2007 Apr; 13(3):336-42. PubMed ID: 17439902
[TBL] [Abstract][Full Text] [Related]
11. Treatment of multiple sclerosis with intravenous immunoglobulin: review of clinical trials.
Sørensen PS
Neurol Sci; 2003 Oct; 24 Suppl 4():S227-30. PubMed ID: 14598048
[TBL] [Abstract][Full Text] [Related]
12. Measures in the first year of therapy predict the response to interferon beta in MS.
Río J; Castilló J; Rovira A; Tintoré M; Sastre-Garriga J; Horga A; Nos C; Comabella M; Aymerich X; Montalbán X
Mult Scler; 2009 Jul; 15(7):848-53. PubMed ID: 19542263
[TBL] [Abstract][Full Text] [Related]
13. [Therapy of multiple sclerosis].
Simó M
Neuropsychopharmacol Hung; 2009 Mar; 11(1):23-6. PubMed ID: 19731815
[TBL] [Abstract][Full Text] [Related]
14. Disability as an outcome in MS clinical trials.
Ebers GC; Heigenhauser L; Daumer M; Lederer C; Noseworthy JH
Neurology; 2008 Aug; 71(9):624-31. PubMed ID: 18480462
[TBL] [Abstract][Full Text] [Related]
15. Clinical parameters to predict response to interferon in relapsing multiple sclerosis.
Fromont A; Debouverie M; Le Teuff G; Quantin C; Binquet C; Moreau T
Neuroepidemiology; 2008; 31(3):150-6. PubMed ID: 18716412
[TBL] [Abstract][Full Text] [Related]
16. Interferon-beta1b in multiple sclerosis: effect on progression of disability and clinical markers of treatment response.
Carmona O; Casado V; Moral E; Alonso-Magdalena L; Martínez-Yélamos A; Martínez-Yélamos S; Martín-Ozaeta G; Arbizu T
Eur Neurol; 2008; 60(6):279-84. PubMed ID: 18824855
[TBL] [Abstract][Full Text] [Related]
17. Multiple sclerosis: interferon beta for some serious forms.
Prescrire Int; 2007 Dec; 16(92):252-7. PubMed ID: 18092425
[TBL] [Abstract][Full Text] [Related]
18. Natalizumab treatment in pediatric multiple sclerosis: a case report.
Borriello G; Prosperini L; Luchetti A; Pozzilli C
Eur J Paediatr Neurol; 2009 Jan; 13(1):67-71. PubMed ID: 18406645
[TBL] [Abstract][Full Text] [Related]
19. Relationship of immunologic abnormalities and disease stage in multiple sclerosis: implications for therapy.
Vaknin-Dembinsky A; Weiner HL
J Neurol Sci; 2007 Aug; 259(1-2):90-4. PubMed ID: 17521671
[TBL] [Abstract][Full Text] [Related]
20. Early treatment.
Comi G
Neurol Sci; 2006 Mar; 27 Suppl 1():S8-12. PubMed ID: 16708191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
